Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Kinetix Pharmaceuticals Inc
Profile last edited on: 4/22/2019      CAGE:       UEI:

Business Identifier: Small molecules: ihibitors of protein kinases
Year Founded
1997
First Award
1995
Latest Award
1998
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

200 Boston Avenue Suite 3000
Medford, MA 02155
   (781) 391-7577
   N/A
   www.kinetixpharm.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

In October 2000, Amgen (NASDAQ:AMGN) - itself an early SBIR Awardee - acquired Kinetix Pharmaceuticals, Kinetix had been focused on the discovery and development of novel orally administered drugs that selectively inhibit enzymes known as protein kinases. Therapeutic areas included Immunology, Asthma/Allergy, Inflammation and Oncology/Angiogenesis

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
1
Conversion Rate
20.00%
Phase I Dollars
$482,000
Phase II Dollars
$737,852
Total Awarded
$1,219,852

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1998 2 NIH $837,852
Project Title: Screen for Nonoligonucleotide Ligands of Specific RNAs
1997 1 NIH $100,000
Project Title: Novel Antimicrobials Based On Arylhydrazones
1996 1 NIH $100,000
Project Title: Development of Small Molecule Antisickling Agents
1995 1 NIH $100,000
Project Title: Novel Antivirals Based on 2-Deoxystreptamine
1995 1 NIH $82,000
Project Title: Screen for Inhibitors of Mycobacterial RNA Polymerase

Key People / Management

  James Lillie

  Andrew A Pakula-not with

  C Wobbe

Company News

There are no news available.